TY - JOUR
T1 - Coverage with evidence development, only in research, risk sharing, or patient access scheme?
T2 - A framework for coverage decisions
AU - Walker, Simon
AU - Sculpher, Mark
AU - Claxton, Karl
AU - Palmer, Stephen John
N1 - Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
PY - 2012/5
Y1 - 2012/5
N2 - Until recently, purchasers' options regarding whether to pay for the use of medical technologies have been binary in nature: a treatment is either covered or not. Policies, however, have emerged that expand the decision options, for example, linking coverage to evidence development, an option increasingly used for treatments with limited/uncertain evidence. There has been little effort to reconcile the features of technologies with the available decision options.
AB - Until recently, purchasers' options regarding whether to pay for the use of medical technologies have been binary in nature: a treatment is either covered or not. Policies, however, have emerged that expand the decision options, for example, linking coverage to evidence development, an option increasingly used for treatments with limited/uncertain evidence. There has been little effort to reconcile the features of technologies with the available decision options.
UR - http://www.scopus.com/inward/record.url?scp=84861141769&partnerID=8YFLogxK
U2 - 10.1016/j.jval.2011.12.013
DO - 10.1016/j.jval.2011.12.013
M3 - Article
C2 - 22583469
SN - 1098-3015
VL - 15
SP - 570
EP - 579
JO - Value in Health
JF - Value in Health
IS - 3
ER -